12,552 findings · published 2017+
- HormonalStrong
GLP-1 RA users had higher rates of type 2 diabetes (55.6% versus 29.5%) compared to nonusers.
Understanding the diabetes status of patients may inform perioperative management strategies.
Supports 2025New - Energy balanceStrong
Obesity is a global epidemic and a chronic, progressive disease.
Recognizing obesity as a chronic disease can influence treatment approaches.
Supports 2022 - MolecularStrong
The study aims to understand the use of semaglutide for treating obesity and its pharmacological mechanism.
The study may provide insights into how semaglutide works, aiding in treatment decisions.
Supports 2022 - Metabolic adaptationStrong
Metabolic benefits of bariatric surgery may fatigue over time.
Clinicians should monitor patients post-surgery for diminishing metabolic benefits.
Qualifies 2022 - CellularStrong
Over half of patients with type 2 diabetes fail to meet glycemic targets due to clinical inertia.
Practitioners should be aware of the impact of clinical inertia on treatment outcomes.
Supports 2023 - CellularStrong
Microneedle (MN)-based technologies provide a painless drug delivery approach that targets adipose tissue directly, minimizing systemic exposure and reducing the required dosage.
Practitioners may consider MNs as a viable alternative for delivering anti-obesity medications effectively.
Supports 2025New - MolecularStrong
The use of nano-based medications through transdermal delivery is important for effective obesity treatment.
Practitioners should consider incorporating nano-based medications for better treatment outcomes.
Supports 2025New - HormonalStrong
Tirzepatide's effect is largely mediated by its GIP component.
Understanding that GIP mediates tirzepatide's effects can help practitioners optimize treatment strategies.
Supports 2022 - Energy balanceStrong
Tirzepatide has a half-life of five days, allowing for once-weekly administration.
Practitioners can schedule tirzepatide administration once a week due to its five-day half-life.
Supports 2022 - CellularStrong
Powerlifters exhibited significantly less shoulder extension and horizontal abduction, and hip flexion, extension, and adduction than recreationally strength-trained men.
Powerlifters may need to address limitations in shoulder and hip ROM to optimize performance.
Supports 2022 - HormonalStrong
No statistically significant differences in resting blood variables or body composition were observed between the AEL and TRAD protocols after 4 weeks of training.
Practitioners may not expect significant changes in hormonal responses or body composition from AEL compared to traditional training.
Refutes 2024 - HormonalStrong
Results marginally favored the use of AEL, but did not support significant improvements in body composition or hormonal responses.
AEL may have slight advantages, but practitioners should not expect major changes in outcomes.
Qualifies 2024 - Metabolic adaptationStrong
Canagliflozin has shown benefits in reducing progression of renal disease and heart failure in patients with type 2 diabetes.
Canagliflozin may be a beneficial treatment option for managing renal and heart health in diabetic patients.
Supports 2023 - HormonalStrong
The combination of canagliflozin and metformin in a single tablet may improve medication adherence in type 2 diabetes.
Using a fixed-dose combination may enhance patient compliance with diabetes treatment regimens.
Supports 2023 - CellularStrong
The goal of management in T2D patients with significant fibrosis is to slow the progression of liver disease and reduce associated clinical events.
Clinicians should aim to adapt therapies to manage liver disease progression in diabetic patients.
Supports 2025New - Energy balanceStrong
The amount of excess weight reduction after bariatric surgery varies by procedure, with laparoscopic adjustable gastric banding reducing excess weight by 49% and Roux-en-Y gastric bypass by 76%.
Practitioners should inform patients about expected weight loss outcomes based on the type of surgery.
Supports 2017 - MolecularStrong
Coconut oil and kernel flakes failed to induce favorable lipid changes comparable to coconut milk supplementation.
Coconut oil and kernel flakes may not be effective for improving lipid profiles compared to coconut milk.
Supports 2024 - MolecularStrong
The MC4R gene variant rs17782313 is directly associated with the risk of metabolic syndrome (MetS) in obese adults (B = 0.010; P = 0.023).
Genetic testing for the MC4R variant may help identify individuals at higher risk for metabolic syndrome.
Supports 2022 - MolecularStrong
Glycemic index (GI) and glycemic load (GL) mediate the relationship between the MC4R variant and LDL cholesterol (LDL-C) levels.
Dietary management focusing on GI and GL may help mitigate LDL-C levels in genetically susceptible individuals.
Supports 2022 - NeuralStrong
RIR rating accuracy did not significantly improve over time.
Practitioners should not expect RIR rating accuracy to improve significantly with time alone.
Refutes 2023 - Energy balanceStrong
No competitor characteristic predicted any of the resistance training variables manipulated during peak week.
Competitors may not need to tailor their training adjustments based on individual characteristics during peak week.
Refutes 2024 - CellularStrong
The placebo group and interruption group showed a reduction in power output during the third sprint compared to the maintenance group.
Avoiding interruption of beta-alanine supplementation may be crucial for maintaining sprint performance.
Supports 2020 - NeuralStrong
The placebo group experienced a higher percentage of fatigue and higher subjective perception of exertion compared to the maintenance group.
Supplementation with beta-alanine may help reduce perceived exertion and fatigue during repeated sprints.
Supports 2020 - Energy balanceStrong
There is a significant multiplicative interaction of cardiovascular autonomic neuropathy (CAN) and sex on both mortality outcomes.
Understanding the interaction between CAN and sex can improve risk assessment and management strategies in diabetes care.
Supports 2025New